| Literature DB >> 31503512 |
Sara L Jepsen1,2, Kaare V Grunddal1, Nicolai J Wewer Albrechtsen1,3, Maja S Engelstoft2, Maria B N Gabe1, Elisa P Jensen1, Cathrine Ørskov1, Steen S Poulsen1, Mette M Rosenkilde1, Jens Pedersen4, Fiona M Gribble5, Frank Reimann5, Carolyn F Deacon1, Thue W Schwartz2, Andreas D Christ6, Rainer E Martin6, Jens J Holst1,2.
Abstract
DPP-4 inhibitors, used for treatment of type 2 diabetes, act by increasing the concentrations of intact glucagon-like peptide-1 (GLP-1), but at the same time, they inhibit secretion of GLP-1, perhaps by a negative feedback mechanism. We hypothesized that GLP-1 secretion is feedback regulated by somatostatin (SS) from neighboring D-cells, and blocking this feedback circuit results in increased GLP-1 secretion. We used a wide range of experimental techniques, including gene expression analysis, immunohistochemical approaches, and the perfused mouse intestine to characterize the paracrine circuit controlling GLP-1 and SS. We show that 1) antagonizing the SS receptor (SSTr) 2 and SSTr5 led to increased GLP-1 and SS secretion in the mouse, 2) SS exhibits strong tonic inhibition of GLP-1 secretion preferentially through SSTr5, and 3) the secretion of S was GLP-1 receptor dependent. We conclude that SS is a tonic inhibitor of GLP-1 secretion, and interventions in the somatostain-GLP-1 paracrine loop lead to increased GLP-1 secretion.Entities:
Keywords: GLP-1; SSTr antagonist; paracrine loop; somatostatin; somatostatin receptors
Mesh:
Substances:
Year: 2019 PMID: 31503512 PMCID: PMC6962500 DOI: 10.1152/ajpendo.00239.2019
Source DB: PubMed Journal: Am J Physiol Endocrinol Metab ISSN: 0193-1849 Impact factor: 4.310